UroGen Pharma (URGN) Change in Receivables (2018 - 2026)
UroGen Pharma (URGN) posted Change in Receivables of $22.3 million for Q1 2026, up 66.9% on a QoQ basis from $13.4 million in Q4 2025, and up 3462.95% year-over-year from $626727.5 in Q1 2025.
UroGen Pharma (URGN) Change in Receivables (2018 - 2026) Analysis & Trends
UroGen Pharma's Change in Receivables history runs 8 years deep, the most recent figure standing at $22.3 million for Q1 2026.
- Quarterly Change in Receivables rose 3462.95% year-over-year to $22.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.8 million (up 552.81% YoY) and the FY2025 annual result came in at $12.8 million, up 163.02% from the prior year.
- Change in Receivables was $22.3 million for Q1 2026 at UroGen Pharma, up from $13.4 million in the prior quarter.
- Across five years, Change in Receivables topped out at $22.3 million in Q1 2026 and bottomed at -$2.7 million in Q3 2023.
- A 5-year average of $2.6 million and a median of $54000.0 in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2024 — Change in Receivables plunged 509.0% — and 2026, when it soared 3462.95%.
- UroGen Pharma's Change in Receivables stood at $3.3 million in 2022, then retreated by 20.73% to $2.6 million in 2023, then tumbled by 196.3% to -$2.5 million in 2024, then surged by 635.16% to $13.4 million in 2025, then jumped by 66.9% to $22.3 million in 2026.
- Business Quant data shows URGN's Change in Receivables at $22.3 million in Q1 2026, $13.4 million in Q4 2025, and $54000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | UroGen Pharma | 2.05 Bn | 1.91 Bn | 46.82 Mn | 22.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.33 Mn |
| Mar 31, 2026 | 22.33 Mn |
| Dec 31, 2025 | 13.38 Mn |
| Dec 31, 2025 | 13.38 Mn |
| Sep 30, 2025 | 54,000.00 |
| Sep 30, 2025 | 54,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | -664,000.00 |
| Mar 31, 2025 | -664,000.00 |
| Dec 31, 2024 | -2.50 Mn |
| Dec 31, 2024 | -2.50 Mn |
| Sep 30, 2024 | 5.39 Mn |
| Sep 30, 2024 | 5.39 Mn |
| Jun 30, 2024 | 3.26 Mn |
| Jun 30, 2024 | 3.26 Mn |
| Mar 31, 2024 | -1.29 Mn |
| Mar 31, 2024 | -1.29 Mn |
| Dec 31, 2023 | 2.60 Mn |
| Dec 31, 2023 | 2.60 Mn |